Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Dose-dense Temozolomide in Recurrent Glioblastoma
NCT03660761Phase 2Completed
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in glioblastoma (GBM). Primary endpoint: Response to treatment at 3 months. Started Mar 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03660761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03660761.